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Abstract  30 
Biofilm formation is often associated with persistent Candida albicans infections. 
Treatment of these infections is difficult since sessile C. albicans cells show an 
increased resistance towards antifungal agents. The molecular mechanisms behind 
biofilm resistance in C. albicans are not yet understood. In the present study, we 
investigated the transcriptional response in young and mature in vitro grown biofilms 35 
after a short and longer exposure time to high doses of fluconazole or amphotericin 
B. Treatment of biofilms with high doses of antifungal agents resulted in a drug-
specific transcriptional response. Exposure of biofilms to fluconazole induced an 
upregulation of genes encoding enzymes involved in the ergosterol biosynthesis 
(ERG1, ERG3, ERG11 and ERG25). Treatment of biofilms with amphotericin B 40 
resulted in an overexpression of KRE1 and SKN1, two genes encoding proteins 
involved in the β-1,6-glucan biosynthesis. Our data indicate that sessile C. albicans 
cells show a controlled regulation of gene expression as they quickly mount a drug-
specific transcriptional response in the presence of high doses of antifungal agents. 
These transcriptional changes suggest an upregulation of the ergosterol biosynthesis 45 
(fluconazole) and an upregulation of the β-1,6-glucan biosynthesis (amphotericin B) 
in sessile C. albicans cells, that might contribute to a resistant biofilm phenotype.  
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1. Introduction 
Candida albicans is a commensal fungus of healthy human individuals that can 
cause superficial and systemic infections when the immune defences are repressed 
or when the normal microbial flora is disturbed (Odds, 1988). Various antifungal 
agents are used to treat these infections, including azoles and polyenes (Pappas et 55 
al., 2004). Fluconazole (FLC) belongs to the azoles and interferes with the ergosterol 
biosynthesis by binding to the ERG11 gene product, lanosterol 14-α-demethylase 
(Richardson, 1990). The latter enzyme is crucial for ergosterol production, and 
inhibition of its activity results in disruption of the cell membrane leading to growth 
inhibition of the fungus (Kelly et al., 1993). It is known that long-term, low level use of 60 
FLC results in the development of azole resistance in C. albicans (Franz et al., 1998). 
Amphotericin B (AMB) is a member of the polyene family (Warnock, 1991). This 
molecule binds to ergosterol and forms pores resulting in a disorganized membrane 
with increased permeability (Brajtburg et al., 1990). In addition, AMB induces cell 
damage by generating lethal reactive oxygen species (Brajtburg et al., 1990). 65 
Development of resistance against this antifungal agent has also been reported, but 
is less frequent (Ellis, 2002). 
The molecular mechanisms of antifungal resistance in C. albicans have been well 
studied and changes in gene expression have frequently been reported in resistant 
clinical isolates (Sanglard, 2002; White, 1997; White et al., 1998). FLC resistance in 70 
particular is associated with overexpression of ERG11 (Franz et al., 1998; Lopez-
Ribot et al., 1998). Changes in the expression of other ERG genes such as ERG3 
and ERG25 have also been observed (Henry et al., 2000). In addition, genes 
encoding efflux pumps (MDR1, CDR1 and CDR2) are often upregulated in FLC-
resistant isolates (Lopez-Ribot et al., 1998; Rogers and Barker, 2003; White et al., 75 
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2002). Upregulation of ERG genes and of genes encoding efflux pumps were also 
detected in planktonic cells after exposure to FLC in vitro (Hernáez et al., 1998; 
Lepak et al., 2006). In vitro exposure of planktonic cells to AMB is correlated with 
underexpression of ERG3 and ERG11, indicating that changes in the sterol 
composition are important for AMB resistance in C. albicans (Liu et al., 2005). 80 
Furthermore, changes in the β-1,6-glucan biosynthesis have also been proposed as 
a resistance mechanism against AMB (Gale, 1986). SKN1 and KRE1, two genes 
involved in the β-1,6-glucan biosynthesis (Mio et al., 1997) were found to be 
differentially expressed after in vitro exposure of C. albicans planktonic cells to 
caspofungin, but not to AMB (Liu et al., 2005). 85 
C. albicans infections are often associated with the formation of biofilms (Douglas, 
2003); biofilms are three-dimensional structures of yeast cells and filaments that are 
embedded in an extracellular matrix (Kumamoto, 2002). Sessile C. albicans cells 
(cells in a biofilm) are phenotypically different from planktonic cells (cells that are not 
attached to a surface), with one of the most prominent features being the increased 90 
resistance towards antifungal agents (Chandra et al., 2001; Hawser and Douglas, 
1995). Therefore, eradication of biofilms and treatment of the associated infections 
are very difficult (Kuhn and Ghannoum, 2004). In order to develop novel and effective 
anti-biofilm strategies it is essential to understand the molecular mechanisms of 
biofilm resistance. However, antifungal resistance in C. albicans biofilms is a complex 95 
phenomenon, and multiple mechanisms are likely to be involved (Kuhn and 
Ghannoum, 2004). It has been reported that genes encoding efflux pumps are highly 
expressed in young biofilms (Mateus et al., 2004; Mukherjee et al., 2003; Ramage et 
al., 2002), while reduced ergosterol levels provide a possible resistance mechanism 
in mature biofilms (Mukherjee et al., 2003). Furthermore, the presence of resistant 100 
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subpopulations in biofilms in the absence of antifungal agents has also been 
proposed as a cause of intrinsic biofilm resistance (Khot et al., 2006). Recently, it 
was demonstrated that the majority of the biofilm population was killed after exposure 
to high doses of AMB, and that only a small fraction of cells (persisters) survives the 
treatment (LaFleur et al., 2006). However, at present it is not known which 105 
mechanisms sessile cells use to survive in the presence of high doses of antifungal 
agents. Investigating the molecular mechanisms of resistance in persisters will help 
to understand resistance in C. albicans biofilms.  
The goal of the present study was to investigate the expression of genes, known to 
be regulated in response to antifungal agents in planktonic cells or known to be 110 
expressed in resistant strains, in C. albicans biofilms. For this, young (0.5 h and 1 h) 
and mature (24 h and 72 h) biofilms were grown after a short (1 h) and longer (22 h) 
exposure time to high doses of FLC or AMB, and also after removal of the antifungal 
drugs. The expression of genes encoding efflux pumps (MDR1, CDR1 and CDR2), 
genes encoding enzymes involved in the ergosterol biosynthesis (ERG1, ERG3, 115 
ERG11 and ERG25) and genes encoding proteins involved in the β-1,6-glucan 
biosynthesis (KRE1 and SKN1) were quantified, using RT-qPCR (Reverse 
Transcriptase quantitative PCR). 
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2. Materials and Methods  
2.1. Strains  120 
C. albicans strain SC5314 (American Type Culture Collection MYA-2876) was used 
throughout the study. Cells were stored at –80 °C in Microbank tubes (Prolab 
Diagnostics, Ontario, Canada) and routinely transferred to Sabouraud Dextrose Agar 
plates (SDA; Oxoid, Hampshire, UK). These were incubated at 37 °C for 24 h.  
 125 
2.2. Biofilm growth 
C. albicans SC5314 biofilms were grown on silicone disks in 24-well microtiter plates 
(TPP, Trasadingen, Switzerland). Silicone sheets were prepared from a medical 
grade silicone rubber kit (Q7-4735; Dow Corning Corp., Midland, MN, USA) 
according to the manufacturer’s instructions. Thirteen-millimetre diameter disks were 130 
punched from the sheets, subsequently washed with a detergent (2% RBS35 
solution; Sigma, St. Louis, MO, USA), rinsed with MilliQ water (Millipore, Billerica, 
MA, USA) and heat-sterilized. Start cultures were prepared by incubating C. albicans 
cells for 16 h in Sabouraud Dextrose Broth (SDB; Oxoid, Hampshire, UK) at 37 °C in 
a water bath with shaking; cells were subsequently washed three times with and 135 
finally resuspended in 1 ml 0.9% (w/v) NaCl. A 0.4% cell suspension was prepared in 
Yeast Nitrogen Base (YNB; BD, Franklin Lakes, NJ, USA) supplemented with 50 mM 
glucose (Sigma, St. Louis, MO, USA); this cell suspension contains approx. 5% 
filaments (Nailis et al., 2009). One ml of this suspension was added to each well and 
plates were incubated for 30 min (0.5 h old biofilms) or 1 h at 37 °C. Silicone disks 140 
were then washed three times with 1 ml 0.9% (w/v) NaCl to remove non-adherent 
cells. Disks were placed in new plates, 1 ml diluted YNB (1:5; final glucose 
concentration: 10 mM) (YNB 0.2x) was added to each well and plates were further 
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incubated for 24 h or 72 h at 37 °C. Biofilm structures were visualized using confocal 
laser scanning microscopy (CLSM), as described previously (Nailis et al., 2009).  145 
 
2.3. Antifungal  agents  
Diflucan® (Pfizer, New York, NY, USA) and Fungizone®  (Bristol-Myers Squibb, New 
York, NY, USA) were the pharmaceutical formulations used. Diflucan contains 2000 
mg/l of FLC. Fungizone contains AMB powder that was dissolved in MilliQ water and 150 
further diluted to obtain stock solutions of 64 mg/l. Aliquots of both antifungal agents 
were stored at -80 °C. The minimal inhibitory concentrations (MICs) of FLC and AMB 
were determined according to the European Committee for Antimicrobial 
Susceptibility Testing (EUCAST) procedure (Cuenca-Estrella et al., 2003).  
 155 
2.4.Treatment of biofilms with antifungal agents  
Biofilms were grown as described above. Silicone disks were subsequently 
transferred to new 24-well microtiter plates, and antifungal agents were added (final 
concentration of 1000 mg/l for FLC and 32 mg/l for AMB, in buffered antifungal-free 
medium). RPMI-1640 2x supplemented with 200 mM glucose and buffered to pH 7.0 160 
with 330 mM MOPS (Sigma, St. Louis, MO, USA) was used for this purpose. Control 
biofilms were grown in buffered RPMI without antifungal agents. Plates were 
incubated at 37 °C for 1 h or 22 h, after which cells were washed three times with 
0.9% (w/v) NaCl. For the regrowth experiments, biofilms were treated for 22 h after 
which they were washed five times with 1 ml of 0.9% (w/v) NaCl, and disks were 165 
transferred to new 24-well microtiter plates. One ml of buffered RPMI was added to 
the wells and plates were further incubated up to 24 h at 37 °C.  
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2.5. Cell quantification 
To enumerate the number of culturable sessile cells, plating was used. Silicone disks 170 
were transferred to 10 ml SDB and cells were subjected to three cycles of 30 s 
sonication (Branson 3510, 42 kHz, 100 W; Branson Ultrasonics Corp., Danbury, CT, 
USA) and 30 s vortex mixing. Using this procedure, all cells were removed from the 
silicone and clumps of cells were broken apart, while viability and culturability of cells 
were not affected (data not shown). Serial tenfold dilutions of the resulting cell 175 
suspensions were plated on SDA and plates were incubated for 24 h at 37 °C, after 
which colonies were counted. The experiments were performed at least in triplicate 
(independent biofilm experiments; biological replicates) with 4 disks per biofilm 
experiment (technical replicates) (n ≥ 12). Independent sample t-tests were carried 
out using SPSS 15.0 software to determine whether differences were statistically 180 
significant (p<0.05). Reductions were considered biologically relevant when a 
statistically significant reduction (p<0.05) of at least 1 log10 unit was observed. 
 
2.6. RT-qPCR 
Biofilms were grown and treated with antifungal agents as described above. Biofilms 185 
were then washed with 1 ml 0.9% (w/v) NaCl, and subjected to sonication and vortex 
mixing as described above. RNA extraction, cDNA synthesis and RT-qPCR were 
performed as described previously (Nailis et al., 2006). Experiments were carried out 
in triplicate using starting material from independent biofilm experiments (biological 
replicates). Full-length gene sequences were obtained from the C. albicans database  190 
(http://www-sequence.stanford.edu/group/candida/search.html). Primers and MGB 
Taqman probes were designed using Primer Express software (Applied Biosystems, 
Foster City, CA, USA). Sequences of the primers and MGB Taqman probes 
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designed in the present study are listed in Table 1. The sequences of the primers 
and probes for the reference genes have been reported previously (Nailis et al., 195 
2006). RT-qPCR data were normalized by geometric averaging of five internal 
reference genes. ACT1, RIP, RPP2B, PMA1 and LSC2 were used for this purpose 
as they have previously shown to be stably expressed in C. albicans biofilms (Nailis 
et al., 2006). Following normalization, normalized relative quantities were used to 
calculate relative gene expression levels as described previously (Nailis et al., 2006). 200 
Gene expression levels (fold over- or underexpression) in biofilms in the absence of 
antifungal agents were calculated as the expression of a gene in biofilms, relative to 
its expression in start cultures (planktonic cells grown for 16 h in SDB at 37°C). Gene 
expression levels (fold up- or downregulation) in biofilms treated with antifungal 
agents were calculated as the expression of a gene in biofilms treated with FLC or 205 
AMB, relative to its expression in untreated biofilms. Gene expression levels (fold up- 
or downregulation) in biofilms after removal of the antifungal agent were calculated 
as the expression of a gene in biofilms after regrowth, relative to its expression in 
biofilms after treatment. Confidence intervals were calculated to determine whether 
differences in gene expression were statistically significant between two biological 210 
conditions (p<0.05). 
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3. Results and Discussion 
3.1. Biofilm formation on silicone disks in microtiter plates 
Young biofilms contained 2.5x104 CFU/disk after 0.5 h and 5.0x104 CFU/disk after 1 
h, whereas mature biofilms contained 6.3x106 CFU/disk (Table 2). CLSM analysis of 215 
a 1 h old biofilm showed mainly yeast cells that were adhered to the silicone surface 
(Fig. 1A). After 24 h (Fig. 1B) and 72 h (data not shown) biofilms showed a three-
dimensional structure of mainly yeast cells and few filaments, embedded in an 
extracellular matrix. Similar structures were obtained in previous studies (Chandra et 
al., 2001; Zhao et al., 2006), although we observed less filaments. This is likely due 220 
to differences in growth conditions as we used YNB for biofilm growth in our model 
system. Previous studies frequently use abiotic surfaces that are incubated with fetal 
bovine serum prior to biofilm formation; serum is known to induce filamentation in C. 
albicans (Ponton et al., 1994).  
 225 
3.2. Effect of antifungal agents on pre-grown biofilms 
In the present study, we wanted to determine whether the age of the biofilm affects 
the activity of antifungal agents and whether this anti-biofilm activity is dependent on 
the exposure time. For this, we used very high doses of FLC (1000 mg/l; 8000 times 
the MIC) and AMB (32 mg/l: 256 times the MIC). These concentrations were selected 230 
because they resulted in the survival of only a small fraction of cells (AMB) or 
because they resulted in tolerance (FLC) for mature biofilms. No antifungal effect 
was observed after treatment of mature biofilms with FLC for 1 h or 22 h, indicating 
that mature biofilms are tolerant to high doses of FLC (Table 2); this confirms 
previous observations (Chandra et al., 2001; Hawser and Douglas, 1995; Mukherjee 235 
et al., 2003; Ramage et al., 2002). Prolonged incubation with FLC (up to 144 h) did 
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not result in a reduction in cell number (data not shown). However, when young 
biofilms (0.5 h and 1 h) were treated for 22 h with FLC, only approx. 2.5x104 CFU 
were recovered from the silicone disks (Table 2). Prolonged incubation of young 
biofilms with high doses of FLC resulted in a reduction in cell number as approx. 240 
3.2x103 CFU per disk were recovered after 144 h. These findings indicate that high 
doses of FLC have an antifungal effect on young biofilms. Previous studies 
demonstrated that adherent C. albicans cells are as tolerant to FLC as mature 
biofilms, but in these studies lower FLC concentrations (≤ 256 mg/l) were used 
(Mateus et al., 2004; Mukherjee et al., 2003).  245 
Treatment of mature biofilms for 22 h with 32 mg/l of AMB resulted in a 99.5 % 
reduction in cell number, indicating that only a small fraction of cells, likely 
“persisters”, survived the treatment (Table 2) (p<0.05). AMB was already found to 
show activity against mature biofilms at a concentration of ≥ 1 mg/l (Chandra et al., 
2001; Hawser and Douglas, 1995; Kuhn et al., 2002), and exposure of mature 250 
biofilms to high doses of this antifungal agent is known to result in the survival of 
persisters (LaFleur et al., 2006). Recently, it was demonstrated that the presence of 
persisters in C. albicans biofilms is strain-dependent, and that biofilms formed by C. 
albicans strain SC5314 contain a very low fraction of persisters only after exposure to 
50 mg/l of AMB (Al-Dhaheri and Douglas, 2008). However, different methods for 255 
biofilm growth were used, and this could explain why we were able to detect 
persisters in C. albicans SC5314 biofilms after treatment with 32 mg/l of AMB. 
Combined, these findings indicate that the presence of persisters in C. albicans 
biofilms is not only strain-dependent, but also seems to be dependent on the biofilm 
model system used. A short exposure of mature biofilms to AMB also resulted in the 260 
presence of persisters, as similar reductions in cell number were observed after 1 h 
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and after 22 h of treatment (Table 2). Longer treatment (up to 144 h) did not result in 
more eradication (data not shown). When young biofilms (1 h old) were treated with 
AMB for 1 h or 22 h, approx. 99.5 and 96.8 % of the population was killed, 
respectively (Table 2). Similar results were obtained for young biofilms grown for 0.5 265 
h (Table 2). Thus, irrespective of the age of the biofilm, a similar fraction of the cell 
population survives treatment with high doses of AMB. Chandra et al. (2001) found 
that resistance to AMB develops at later stages of biofilm formation. However, these 
authors used different biofilm growth conditions, different susceptibility methods and 
lower concentrations of AMB (Chandra et al., 2001), which likely explain the 270 
observed discrepancies. Taken together, our data show that a small fraction (1 to 4 
%) of persisters are present in both young and mature biofilms, even after a short 
exposure to AMB.  
CLSM analysis confirmed our findings as treatment of 72 h old biofilms with FLC for 
22 h has no effect (Fig. 1C), while exposure to AMB for 22 h resulted in a disruption 275 
of the three-dimensional structure and a reduction in cell number (Fig. 1D). For AMB, 
similar results were obtained in a previous study (Hawser and Douglas, 1995). 
 
3.3. Gene expression in biofilms in the absence of antifungal agents 
In a next set of experiments, gene expression was quantified in biofilms relative to 280 
gene expression in start cultures (prior to treatment with antifungal agents). By doing 
so, we observed a marked overexpression of SKN1 in young biofilms; this gene was 
27.0 ± 13.5 and 22.1 ± 13.8 (mean ± SEM) fold upregulated after 0.5 h and 1 h of 
biofilm growth, respectively. Upregulation of SKN1 suggests a reorganization of the 
β-1,6-glucan content in the cell wall, a mechanism which is known to be implicated in 285 
transient AMB resistance in C. albicans (Gale, 1986; Liu et al., 2005). Khot et al. 
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(2006) recently found that the expression of SKN1 was induced in a subpopulation of 
cells which are most closely in contact with the silicone surface. The majority of cells 
in a young biofilm grown in our model system are also in intimate contact with the 
silicone surface (see Fig. 1A). Combined, these data suggest that contact sensing 290 
with the silicone surface induces the expression of SKN1, which may render sessile 
C. albicans cells resistant to AMB even in the absence of antifungal drugs. On the 
other hand, overexpression of SKN1 could be a sign of biofilm growth as this gene is 
highly upregulated only in young biofilms. 
No statistical significant changes in the expression of genes encoding efflux pumps, 295 
nor in KRE1 or ERG gene expression were observed between biofilms and start 
cultures (data not shown). However, previous studies showed that MDR1, CDR1, 
CDR2 are overexpressed in young biofilms (Mateus et al., 2004; Mukherjee et al., 
2003; Ramage et al., 2002). Discrepancies between these studies and our results 
are likely due to the fact that we detected a high number of transcripts for MDR1, 300 
CDR1, CDR2 (evidenced by low cycle threshold values) not only in young biofilms 
but also in start cultures (data not shown). Similarly to Mukherjee et al (2003), we 
detected lower gene expression levels for CDR1 and MDR1 after 24 h of biofilm 
growth than after 1 h (p<0.05), confirming that the expression of genes encoding 
efflux pumps is higher in young biofilms. 305 
 
3.4. Transcriptional response to FLC in biofilms  
We also investigated gene expression in biofilms in the presence of high doses of 
FLC. Gene expression in biofilms treated with high doses of FLC was compared to 
gene expression in untreated biofilms, and results are listed in Table 3. After 1 h of 310 
treatment with high doses of FLC, young biofilms showed an upregulation of ERG25, 
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while in mature biofilms an overexpression of ERG1, ERG3, ERG11 and ERG25 was 
observed. After longer treatment, upregulation of ERG genes was more pronounced 
in young biofilms, but not in mature biofilms (Table 3). It is possible that the response 
of ERG gene expression in 24 h old biofilms is attenuated because mature biofilms 315 
are tolerant to high doses of FLC. However, we observed a high upregulation of ERG 
genes in tolerant 72 h old biofilms after 22 h of treatment with high doses of FLC. In 
order to better understand the role of ERG gene expression in tolerance and 
sensitivity in biofilms, we examined gene expression in young biofilms treated with 
0.5 mg/l of FLC. Young biofilms were tolerant to low doses of FLC as a mature 320 
biofilm with approx. 2.0x106 CFU per disk was obtained after 22 h of treatment. As 
can be seen in Fig. 2, ERG genes were overexpressed in tolerant young biofilms, 
although the fold upregulations were lower than those observed in young biofilms 
after exposure to high doses of FLC. Upregulation of ERG genes was previously 
observed in planktonic cells after in vitro exposure to FLC (Lepak et al., 2006) and 325 
also after exposure to another azole, itraconazole (De Backer et al., 2001). 
Combined, these data suggest a general response of the expression of ERG genes 
to FLC sensing in biofilms and planktonic cells. The overexpression of ERG genes is 
probably related to biofilm resistance, but is not sufficient as sensitive biofilms show a 
similar gene expression pattern as tolerant biofilms.  330 
Surprisingly, no statistical significant overexpression of genes encoding efflux pumps 
were observed in biofilms after exposure to high doses of FLC (Table 3). Similar 
results were obtained after treatment of planktonic cells with itraconazole (De Backer 
et al., 2001). However, when planktonic cells were exposed to FLC an upregulation 
of CDR1 was observed (Hernáez et al., 1998). In the current study, an 335 
overexpression of CDR2 was found in tolerant young biofilms (Fig. 2), suggesting 
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that efflux pumps play a role in biofilm resistance in a dose-dependent manner. 
Furthermore, we observed an overexpression of KRE1 and SKN1 in young biofilms 
after exposure to low doses of FLC (Fig. 2). This could be a sign of biofilm growth as 
SKN1 was also induced in young biofilms in the absence of antifungal agents (see 340 
above).  
Together, the current study showed an upregulation of genes encoding enzymes 
involved in the ergosterol biosynthesis in sessile cells in the presence of FLC. This 
transcriptional response may contribute to biofilm resistance in C. albicans. 
 345 
3.5. Transcriptional response to AMB in biofilms  
We also investigated gene expression in biofilms in the presence of high doses of 
AMB. Gene expression in biofilms treated with AMB was compared to gene 
expression in untreated biofilms, and results are listed in Table 4. No statistical 
significant differences in the expression of ERG3, ERG11 and ERG25 were observed 350 
between biofilms exposed to AMB and untreated biofilms. A marked overexpression 
of SKN1 was seen in young and mature biofilms already after 1 h of exposure (Table 
4), and its expression was even more induced after 22 h. Furthermore, KRE1 was 
significantly upregulated in young biofilms (1 h old) after 1 h of treatment, and in 
mature biofilms (24 h old) both after 1 h and 22 h (p<0.05). In addition, ERG1 was 355 
significantly overexpressed in biofilms after 22 h of treatment (p<0.05). As mentioned 
above, exposure of biofilms to high doses of AMB resulted in the survival of a small 
fraction of cells, and these persisters seem to exhibit high expression levels of SKN1 
(and to a lesser extent KRE1 and ERG1). Khot et al. (2006) demonstrated that SKN1 
and KRE1 were highly upregulated in biofilms in the absence of AMB. 360 
Overexpression of SKN1 and KRE1 suggest changes in cell wall maintenance, which 
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in turn could explain the high resistance of biofilms towards AMB (Gale, 1986; Liu et 
al., 2005). Consequently, overexpression of both genes could be responsible for the 
resistant phenotype of persisters in the presence of high doses of AMB on the one 
hand, and also for the intrinsic resistance of biofilms in the absence of AMB on the 365 
other hand (our data and those from Khot et al. [2006]). It has already been 
demonstrated that planktonic cells show a downregulation of ERG3, ERG11 and 
ERG25 after exposure to much lower concentrations of AMB (Liu et al., 2005), 
indicating that biofilms show a specific transcriptional response to AMB. Based on 
our findings, changes in cell wall maintenance could be an important resistance 370 
mechanism in sessile C. albicans cells towards AMB. 
 
3.6. Transcriptional response to removal of the antifungal agent  
To test whether the transcriptional response in biofilms after exposure to antifungal 
agents was transient or permanent, gene expression was investigated in biofilms 375 
after removal of FLC and AMB. For this, biofilms were grown for 72 h, subsequently 
treated with antifungal drugs for 22 h, and further incubated in antifungal-free 
medium. As can be seen in Table 5, biofilms showed a marked overexpression of 
SKN1 after removal of FLC. This gene was 49.6 ± 9.2 and 31.7 ± 6.6 (mean ± SEM) 
fold upregulated after 1 h and 24 h of regrowth, respectively. Overexpression of 380 
SKN1 could be a sign of biofilm regrowth as this gene was also upregulated during 
biofilm formation (see above). Furthermore, the expression of ERG genes remained 
unchanged (Table 5), demonstrating that these genes were still upregulated 24 h 
after removal of FLC. A transient molecular response with upregulation of ERG11, 
CDR1 and CDR2 in the presence of FLC and a downregulation of ERG11 in the 385 
post-exposure period has been observed in planktonic cells (Henry et al., 2000; 
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Lepak et al., 2006). After removal of AMB, gene expression remained unchanged in 
biofilms, except for SKN1; this gene was 4.6 ± 1.2 (mean ± SEM) fold upregulated 1 
h after removal of the antifungal agent (Table 5). Our data indicate that the 
expression of SKN1 is highly induced in C. albicans persisters after exposure to 390 
AMB, and that this gene remains upregulated in biofilms after removal of the 
antifungal agent.  
 
3.7. Concluding remarks 
In the present study, it was demonstrated that high doses of FLC have an antifungal 395 
effect on young biofilms, while mature biofilms were tolerant to this antifungal agent. 
Treatment of young and mature biofilms with high doses of AMB resulted in the 
survival of a small fraction (0.5 to 4 %) of persisters. Exposure of biofilms to FLC 
resulted in an overexpression of genes encoding enzymes involved in the ergosterol 
biosynthesis. However, genes encoding efflux pumps were not regulated in biofilms 400 
in response to high doses of FLC. Treatment of biofilms with high doses of AMB 
resulted in an upregulation of genes encoding proteins involved in the β-1,6-glucan 
biosynthesis. Transcriptional changes in sessile C. albicans cells in the presence of 
antifungal agents suggest an upregulation of the associated biosynthetic pathways, 
thereby contributing to a resistant biofilm phenotype. Future research will provide a 405 
direct elucidation of these resistance mechanisms in sessile C. albicans cells. Taken 
together, our data indicate that young and mature biofilms show a rapid and 
antifungal-specific transcriptional response to exposure with FLC and AMB. This 
molecular adaptation could help to explain the high resistance of C. albicans biofilms 
towards antifungal agents. 410 
 18 
Acknowledgements 
We are grateful to Alistair Brown (Aberdeen University, UK) for sharing C. albicans 
SC5314 with us. We would like to acknowledge Leen Molderez and Marlies De Kezel 
for technical assistance. We are grateful to Jo Vandesompele for providing useful 
advice concerning qPCR data analysis. We kindly acknowledge Ine Lentacker, Kevin 415 
Braeckmans, Stefaan Desmedt and Jo Demeester for the use of the CLSM facilities. 
This work was funded by the Belgian Federation against Cancer and the FWO 
(Fonds voor Wetenschappelijk Onderzoek). 
 19 
References  
1. Al-Dhaheri, R.S., Douglas, L.J., 2008. Absence of amphotericin B-tolerant 420 
persister cells in biofilms of some Candida species. Antimicrob. Agents Chemother. 
52, 1884-1887.  
2. Brajtburg, J., Powderly, W.G., Kobayashi, G.S., Medoff, G., 1990. Amphotericin B: 
Current understanding of mechanisms of action. Antimicrob. Agents Chemother. 34, 
183-188. 425 
3. Chandra, J., Kuhn, D.M., Mukherjee, P.K., Hoyer, L.L., McCormick, T., Ghannoum, 
M.A., 2001. Biofilm formation by the fungal pathogen Candida albicans: 
development, architecture, and drug resistance. J. Bacteriol. 183, 5385-5394. 
4. Cuenca-Estrella, M., Moore, C.B., Barchiesi, F., Bille, J., Chryssanthou, E., 
Denning, D.W., Donnelly, J.P., Dromer, F., Dupont, B., Rex, J.H., Richardson, M.D., 430 
Sancak, B., Verweij, P.E., Rodriguez-Tudela, J.L.; AFST Subcommittee of the 
European Committee on Antimicrobial Susceptibility Testing, 2003. Multicenter 
evaluation of the reproducibility of the proposed antifungal susceptibility testing 
method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee 
of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). 435 
Clin. Microbiol. Infect. 9, 467-474. 
5. De Backer, M.D., Ilyina, T., Ma, X.J., Vandonink, S., Luyten, W.H., Vanden 
Bossche, H., 2001. Genomic profiling of the response of Candida albicans to 
itraconazole treatment using a DNA microarray. Antimicrob. Agents Chemother. 45, 
1660-1670. 440 
6. Douglas, L.J., 2003. Candida biofilms and their role in infection. Trends Microbiol. 
11, 30-36. 
7. Ellis, D., 2002. Amphotericin B: spectrum and resistance. J. Antimicrob. 
Chemother. 49, 7-10. 
8. Franz, R., Kelly, S.L., Lamb, D.C., Kelly, D.E., Ruhnke, M., Morschhäuser, J., 445 
1998. Multiple molecular mechanisms contribute to a stepwise development of 
fluconazole resistance in clinical Candida albicans strains. Antimicrob. Agents 
Chemother. 42, 3065-3072.  
9. Gale, E.F., 1986. Nature and development of phenotypic resistance to 
amphotericin B in Candida albicans. Adv. Microb. Physiol. 27, 277-320. 450 
10. Hawser, S.P., Douglas, L.J., 1995. Resistance of Candida albicans biofilms to 
antifungal agents in vitro. Antimicrob. Agents Chemother. 39, 2128-2131. 
 20 
11. Henry, K.W., Nickels, J.T., Edlind, T.D., 2000. Upregulation of ERG genes in 
Candida species by azoles and other sterol biosynthesis inhibitors. Antimicrob. 
Agents Chemother. 44, 2693-2700. 455 
12. Hernáez, M.L., Gil, C., Pla, J., Nombela, C., 1998. Induced expression of the 
Candida albicans multidrug resistance gene CDR1 in response to fluconazole and 
other antifungals. Yeast. 14, 517-526.  
13. Kelly, S.L., Arnoldi, A., Kelly, D.E., 1993. Molecular genetic analysis of azole 
antifungal mode of action. Biochem. Soc. Trans. 21, 1034-1038. 460 
14. Khot, P.D., Suci, P.A., Miller, R.L., Nelson, R.D., Tyler, B.J., 2006. A small 
subpopulation of blastospores in Candida albicans biofilms exhibit resistance to 
amphotericin B associated with differential regulation of ergosterol and bèta-1,6-
glucan pathway genes. Antimicrob. Agents Chemother. 50, 3708-3716.  
15. Kuhn, D.M, George, T., Chandra, J., Mukherjee, P.K., Ghannoum, M.A., 2002. 465 
Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid 
formulations and echinocandins. Antimicrob. Agents Chemother. 46, 1773-1780. 
16. Kuhn, D.M., Ghannoum, M.A., 2004. Candida biofilm: antifungal resistance and 
emerging therapeutic options. Curr. Opin. Investig. Drugs. 5, 186-197. 
17. Kumamoto, C.A., 2002. Candida biofilms. Curr. Opin. Microbiol. 5, 608-611. 470 
18. LaFleur, M.D., Kumamoto, C.A., Lewis, K., 2006. Candida albicans biofilms 
produce antifungal-tolerant persister cells. Antimicrob. Agents Chemother. 50, 3839-
3846. 
19. Lepak, A., Nett., J., Lincoln, L., Marchillo, K., Andes, D., 2006. Time course of 
microbiologic outcome and gene expression in Candida albicans during and following 475 
in vitro and in vivo exposure to fluconazole. Antimicrob. Agents Chemother. 50, 
1311-1319.  
20. Liu, T.T., Lee, R.E., Barker, K.S., Lee, R.E., Wei, L., Homayouni, R., Rogers, 
P.D., 2005. Genome-wide expression profiling of the response to azole, polyene, 
echinocandin, and pyrimidine antifungal agents in Candida albicans. Antimicrob. 480 
Agents Chemother. 49, 2226-2236. 
21. Lopez-Ribot, J.L., McAtee, R.K., Lee, L.N., Kirkpatrick, W.R., White, T.C., 
Sanglard, D., Patterson, T.F., 1998. Distinct patterns of gene expression associated 
with development of fluconazole resistance in serial Candida albicans isolates from 
human immunodeficiency virus-infected patients with oropharyngeal candidiasis. 485 
Antimicrob. Agents Chemother. 42, 2932-2937. 
 21 
22. Mateus, C., Crow, S.A. Jr., Ahearn, D.G., 2004. Adherence of Candida albicans 
to silicone induces immediate enhanced tolerance to fluconazole. Antimicrob. Agents 
Chemother. 48, 3358-3366. 
23. Mio, T., Yamada-Okabe, T., Yabe, T., Nakajima,T., Arisawa, M., and Yamada-490 
Okabe, H., 1997. Isolation of the Candida albicans homologs of Saccharomyces 
cerevisiae KRE6 and SKN1: expression and physiological function. J. Bacteriol. 179, 
2363-2372.  
24. Mukherjee, P.K., Chandra, J., Kuhn, D.M., Ghannoum, M.A., 2003. Mechanisms 
of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux 495 
pumps and membrane sterols. Infect. Immun. 71, 4333-4340. 
25. Nailis, H., Coenye, T., Van Nieuwerburgh, F., Deforce, D., Nelis, H.J., 2006. 
Development and evaluation of different normalization strategies for gene expression 
studies in Candida albicans biofilms by real-time PCR. BMC Mol. Biol. 7, 25. 
26. Nailis, H., Vandenbroucke, R., Tilleman, K., Deforce, D., Nelis, H., Coenye, T., 500 
2009. Monitoring ALS1 and ALS3 gene expression during in vitro Candida albicans 
biofilm formation under continuous flow conditions. Mycopathologia 167, 9-17. 
27. Odds, F.C., 1988. Meeting Candida and Candidiosis, 2nd ed. Bailliere Tindall, 
London, UK. 
28. Pappas, P.G., Rex, J.H., Sobel J.D., Filler, S.G., Dismukes, W.E., Walsh, T.J., 505 
Edwards, J.E., 2004. Infectious Disease Society of Amerika; Guidelines for treatment 
of candidiasis. Clin. Infect. Dis. 38, 161-189. 
29. Ponton, J., Quindos, G., Arilla, M.C., Mackenzie, D.W., 1994. Simplified 
adsorption method for detection of antibodies to Candida albicans germ tubes. J. 
Clin. Microbiol. 32, 217-219. 510 
30. Ramage, G., Bachmann, S., Patterson, T.F., Wickes, B.L., López-Ribot, J.L., 
2002. Investigation of multidrug efflux pumps in relation to fluconazole resistance in 
Candida albicans biofilms. J. Antimicrob. Chemother. 49, 973-980. 
31. Richardson, K., 1990. The discovery and profile of fluconazole. J. Chemother. 2, 
51-54. 515 
32. Rogers, P.D., Barker, K.S., 2003. Genome-wide expression profile analysis 
reveals coordinately regulated genes associated with stepwise acquisition of azole 
resistance in Candida albicans clinical isolates. Antimicrob. Agents Chemother. 47, 
1220-1227. 
 22 
33. Sanglard, D., 2002. Resistance of human fungal pathogens to antifungal drugs. 520 
Curr. Opin. Microbiol. 5, 379-385. 
34. Warnock, D.W., 1991. Amphotericin B: an introduction. J. Antimicrob. Chemother. 
28, 27-38. 
35. White, T.C., 1997. Increased mRNA levels of ERG16, CDR, and MDR1 correlate 
with increases in azole resistance in Candida albicans isolates from a patient infected 525 
with human immunodeficiency virus. Antimicrob. Agents Chemother. 41, 1482-1487. 
36. White, T.C., Marr, K.A., Bowden, R.A., 1998. Clinical, cellular and molecular 
factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11, 382-
402.  
37. White, T.C., Holleman, S., Dy, F., Mirels, L.F., Stevens D.A., 2002. Resistance 530 
mechanisms in clinical isolates of Candida albicans. Antimicrob. Agents Chemother. 
46, 1704-1713. 
38. Zhao, X., Daniels, K.J., Oh, S.H., Green, C.B., Yeater, K.M., Soll, D.R., Hoyer, 
L.L., 2006. Candida albicans Als3p is required for wild-type biofilm formation on 
silicone elastomer surfaces. Microbiology 152, 2287-2299. 535 
 23 
Legends to figures  
Fig. 1: CLSM images of C. albicans SC5314 biofilms grown for 1 h (Fig. 1 A) and 24 
h (Fig. 1 B) on silicone disks in 24-well microtiter plates. CLSM images of mature C. 
albicans SC5314 biofilms (72 h) treated for 22 h with 1000 mg/l of FLC (Fig. 1C) or 540 
with 32 mg/l of AMB (Fig. 1D). Sessile C. albicans cells were stained with 
Concanavalin A, resulting in red labelled cells and red stained extracellular matrix. 
Scale bar: 10 µm.  
 
Fig. 2: Average gene expression levels in young (1 h) C. albicans SC5314 biofilms 545 
after exposure to low doses of FLC (0.5 mg/l) for 22 h. Gene expression levels (fold 
up- or downregulation) were defined as the expression of a gene in biofilms treated 
with FLC, relative to its expression in untreated biofilms. * represents statistically 
significant difference in gene expression between biofilms treated with FLC and 




Table 1: Sequences of primers and MGB Taqman probes for C. albicans genes used 
in the real-time PCR assays. 
555 
Gene Protein product and/or function Orientation  Sequence (5’ to 3’) 
CDR1 ABC membrane transporter involved in active efflux  




CDR2 ABC membrane transporter involved in active efflux of 




MDR1 MF membrane transporter involved in active efflux of 




ERG1 Squalene epoxidase, catalyzes epoxidation of 




ERG3 C-5 sterol desaturase; introduction of C-5(6) double 




ERG11 Lanosterol 14-α-demethylase, member of the 





ERG25 Putative C-4 methyl sterol oxidase, important for C4 





KRE1 Predicted Glycosyl Phosphatidyl Inositol anchor 




SKN1 N-glycosylated type II membrane protein with a 





Table 2: Average number of sessile C. albicans SC5314 cells (CFU/disk) in untreated 
biofilms and in biofilms treated for 1 h or 22 h with FLC (1000 mg/l) or AMB (32 mg/l). 
 
Average number of sessile C. albicans cells (Log10 CFU/disk) 




















0.5 4.4 ± 0.4 ND ND 4.5 ± 0.6 -0.1 ND ND 3.0 ± 0.9 1.4
c
 
1 4.7 ± 0.4 4.3 ± 0.4 0.4 4.4 ± 0.7 0.3 2.4 ± 0.7 2.3
 c
 3.2 ± 0.7 1.5
c
 
24 6.8 ± 0.3 6.4 ± 0.4 0.4 6.8 ± 0.4 0 4.6 ± 0.3 2.2
 c
 4.5 ± 0.6 2.3
c
 




 Log10 average number of CFU/disk ± SD (n ≥ 12)  
 
b
 Log10 reduction of cells after treatment, compared to the cell number of untreated biofilms at the 560 
same stage of growth. 
c
 Reductions were considered biologically relevant when a statistically significant reduction (p<0.05) of 
at least 1 log10 unit was observed; ND = Not determined. 
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Table 3: Average gene expression levels (with corresponding SEM; n=3) in young (0.5 h and 1 h) and mature (24 h and 72 h) C. 
albicans SC5314 biofilms after exposure to high doses of FLC (1000 mg/l). Gene expression levels (fold up- or downregulation) 565 
were defined as the expression of a gene in biofilms treated with FLC for 1 h or 22 h, relative to its expression in untreated biofilms.  
a 
Statistically significant difference in gene expression between biofilms treated with FLC and untreated biofilms (p<0.05).  
Gene expression levels in biofilms after treatment with high doses of FLC (1000 mg/l) 
Biofilms treated with FLC CDR1 CDR2 MDR1 ERG1 ERG3 ERG11 ERG25 KRE1 SKN1 
Young biofilms (0.5h) + FLC (22h) -2.0 ± 0.6   2.1 ± 0.6 -3.1 ± 1.4 9.8 ± 1.2
a
 6.3 ± 3.1
a
 4.4 ± 1.4
a
 5.7 ± 1.6
a
 -1.8 ± 0.5 2.1 ± 0.8 
Young biofilms (1h) + FLC (1h)   1.0 ± 0.2 1.1 ± 0.2 -1.0 ± 0.2 1.7 ± 0.4 2.5 ± 0.7 2.7 ± 1.0 2.1 ± 0.3
a
 1.3 ± 0.4 1.1 ± 0.3 
Young biofilms (1h) + FLC (22h) 1.0 ± 0.5 4.2 ± 1.4 -1.9 ± 0.9 16.2 ± 1.1
 a
 11.6 ± 4.5
a
 7.4 ± 1.3
a
 8.6 ± 2.6
a
 -1.3 ± 0.5 2.2 ± 1.0 
Mature biofilms (24h) + FLC (1h)   1.0 ± 0.3 -1.1 ± 0.1 1.2 ± 0.4 2.6 ± 0.3
 a
 3.3 ± 0.7
a
 2.7 ± 0.3
a
 2.2 ± 0.4
a
 1.3 ± 0.2 1.2 ± 0.4 
Mature biofilms (24h) + FLC (22h) -2.3 ± 1.0 1.1 ± 0.6 -2.3 ± 1.1 5.0 ± 1.8
 a
 1.5 ± 1.1 3.4 ± 0.8
a
 2.0 ± 0.3
a
 -2.4 ± 1.3 -1.8 ± 0.9 
Mature biofilms (72h) + FLC (22h) 1.8 ± 0.5 2.0 ± 0.4 1.3 ± 0.5 39.3 ± 10.1
 a
 11.3 ± 6.7
a
 23.5 ± 10.2
a
 20.5 ± 11.0
a
 1.7 ± 0.8 2.8 ± 1.3 
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Table 4: Average gene expression levels (with corresponding SEM; n=3) in young (0.5 h and 1 h) and mature (24 h and 72 h) C. 
albicans SC5314 biofilms after exposure to high doses of AMB (32 mg/l). Gene expression levels (fold up- or downregulation) were 
defined as the expression of a gene in biofilms treated with AMB for 1 h or 22 h, relative to its expression in untreated biofilms.  570 
 
Gene expression levels in biofilms after treatment with high doses of AMB (32 mg/l) 
Biofilms treated with AMB ERG1 ERG3 ERG11 ERG25 KRE1 SKN1 
Young biofilms (0.5h) + AMB (22h) 3.8 ± 2.0
a
 2.5 ± 1.7 1.2 ± 0.3 1.7 ± 0.9 1.9 ± 1.3 40.0 ± 32.1
a
 
Young biofilms (1h) + AMB (1h) -1.4 ± 0.3 1.3 ± 0.3 -1.3 ± 0.5 1.0 ± 0.3 6.6 ± 2.1
a
 16.0 ± 6.6
a
 
Young biofilms (1h) + AMB (22h) 3.5 ± 1.9
a
 2.1 ± 1.5 1.2 ± 0.3 1.9 ± 1.0 1.1± 0.6 22.4 ± 12.9
a
 
Mature biofilms (24h) + AMB (1h) -2.2 ± 0.2 1.1 ± 0.1 -1.8 ± 0.2 -1.3 ± 0.3 4.9 ± 1.3
a
 13.0 ± 3.1
a
 
Mature biofilms (24h) + AMB (22h) 4.1 ± 1.4
a
 1.3 ± 0.7 1.2 ± 0.4 2.3 ± 1.0 5.7 ± 2.4
a
 59.9 ± 17.5
a
 




 Statistically significant difference in gene expression between biofilms treated with AMB and untreated biofilms (p<0.05). 
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Table 5: Average gene expression levels (with corresponding SEM; n=3) in C. albicans SC5314 biofilms regrown in antifungal-free 
medium after exposure to high doses of FLC (1000 mg/l) or AMB (32 mg/l). Gene expression levels (fold up- or downregulation) 
were defined as the expression of a gene in biofilms after 1 h or 24 h of regrowth, relative to its expression in biofilms after 575 
treatment with antifungal agents.  
  
a
 Statistically significant difference in gene expression between biofilms after regrowth and biofilms after treatment (p<0.05). ND: Not determined 
Gene expression levels in biofilms after removal of the antifungal agent 
Biofilms after regrowth CDR1 CDR2 MDR1 ERG1 ERG3 ERG11 ERG25 KRE1 SKN1 
FLC + 1h regrowth 1.4 ±  0.4 2.7 ± 2.4 3.5 ± 2.4 -2.9 ± 0.6 -2.6 ± 0.6 -3.6 ± 0.7 -1.6 ± 0.4 3.1 ± 0.8 49.6 ± 9.2
a
 
FLC + 24h regrowth 2.8 ± 0.4 2.2 ± 0.7 5.3 ± 2.0 1.2 ± 0.2 2.4 ± 0.4 1.0 ± 0.1 2.9 ± 0.6 4.6 ± 1.3 31.7 ± 6.6
a
 
AMB + 1h regrowth ND ND ND -1.4 ± 0.7 -1.5 ± 0.5 -1.9 ± 0.1 -1.4 ± 0.4 2.2 ± 0.8 4.6 ± 1.2
a
 
AMB + 24h regrowth ND ND ND 2.5 ± 1.5 2.4 ± 1.5 1.1 ± 0.4 2.5 ± 1.2 3.7 ± 1.6 3.8 ± 1.6 
